Amador Bioscience provides global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies around the world. Backed by premier private equity groups, including Hillhouse Capital Group and Sequoia Capital, Amador is committed to providing mission-critical services required to achieve regulatory approval of a novel therapeutic. Amador’s consulting strategy draws upon the latest technologies, industry best practices, and strict quality control procedures. Well-regarded for facilitating innovative development, Amador has supported a diverse array of clients, ranging from cutting-edge biotech start-ups to multinational pharmaceutical companies, through the deployment of expert services, including clinical pharmacology, DMPK, pharmacometrics, bioanalytical services, precision medicine, biostatistics, statistical programming, clinical development, medical writing, and regulatory submissions.

Amador cofounders have extensive industry experience (Amgen, AstraZeneca and Novartis). Members of our leadership team also possess broad experience from PPD, Quantiles, Crownbio and other leading clinical CROs